Stocks · News reference
InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Dell Technologies (DELL) stock jumps in pre-market trading after reporting better-than-expected Q2 results and raising FY27 guidance. Other gainers include UPC, GTLB, VIVK, UFG, MLEC, FFAI, GPUS, NCPL, and LHSW.
Filed: 2026-08-17 AccNo: 0001493152-26-038624 Size: 441 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the